Effect of Non-Invasive Neuromodulation on Primary Chronic Pain, Including Post-COVID-19
Launched by FEDERAL UNIVERSITY OF ABC · Nov 13, 2024
Trial Information
Current as of August 20, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Healthy individuals, both sexes, aged between 18 and 40 years (first arm).
- • Diagnosis of primary chronic pain (for more than 3 months), such as fibromyalgia (chronic widespread pain), primary chronic headache and orofacial pain, chronic primary visceral pain, post-COVID pain, and chronic primary musculoskeletal pain;
- • In the case of post-COVID-19 pain, the symptoms must be present for at least 12 weeks. The complaints of pain, fatigue, and/or changes in mental health should have started after infection by SARS-Cov-2.
- Exclusion Criteria:
- • Individuals who present dysautonomia;
- • obese individuals with a high abdominal fat index characterized by a waist/hip ratio of 0.80 for women and 0.95 for men;
- • heart disease;
- • diabetes mellitus;
- • vestibular alterations characterized by the Dix-Hallpike maneuver, supine rotation test, arc test, side-lying maneuver, and post-head-shake nystagmus;
- • diagnosis of epilepsy or first-degree family history of epilepsy
- • fever;
- • chronic consumption of alcohol, or other recreational drugs;
- • presence of contraindications for the use of non-invasive neuromodulation;
- • those who become ill with COVID-19 during the data collection period;
- • those who are unable to answer the evaluation questionnaires;
- • those with clinical instability;
- • those who have a previous history of chronic pain or fatigue before contracting COVID-19;
- • those who have neuropathic pain.
About Federal University Of Abc
The Federal University of ABC is a prestigious academic institution dedicated to advancing knowledge and innovation through rigorous research and education. As a clinical trial sponsor, the university leverages its multidisciplinary expertise and state-of-the-art facilities to conduct cutting-edge research that addresses pressing health challenges. Committed to ethical practices and the highest standards of scientific integrity, the Federal University of ABC collaborates with healthcare professionals, industry partners, and regulatory bodies to ensure the successful design, execution, and dissemination of clinical trials aimed at improving patient outcomes and fostering public health advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sâo Bernardo Do Campo, Sao Paulo, Brazil
Patients applied
Trial Officials
Tiago S Lopes, PhD
Study Chair
Federal University of ABC
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported